Mirataz

RSS

mirtazapine

Authorised
This medicine is authorised for use in the European Union.

Overview

Mirataz is a medicine used to produce an increase in bodyweight in cats with long-term conditions known to cause poor appetite and weight loss. It contains the active substance mirtazapine.

This EPAR was last updated on 10/07/2020

Authorisation details

Product details
Name
Mirataz
Agency product number
EMEA/V/C/004733
Active substance
mirtazapine
International non-proprietary name (INN) or common name
mirtazapine
Species
Cats
Anatomical therapeutic chemical veterinary (ATCvet) codes
QN06AX11
Publication details
Marketing-authorisation holder
Dechra Regulatory B.V.
Revision
1
Date of issue of marketing authorisation valid throughout the European Union
10/12/2019
Contact address

Handelsweg 25
5531 AE Bladel
The Netherlands

Product information

24/06/2020 Mirataz - EMEA/V/C/004733 - T/0001

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

  • Psychoanaleptics

  • Antidepressants in combination with psycholeptics

Therapeutic indication

For bodyweight gain in cats experiencing poor appetite and weight loss resulting from chronic medical conditions.

Assessment history

How useful was this page?

Add your rating
Average
2 ratings